Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $27 from $26 and keeps a Buy rating on the shares after the FDA lifted the clinical hold on the MAGNITUDE Phase III trial. The firm views the resolution as a “reassuring step.” Intellia is working to get its nex-z franchise back on track and the news “removes a major overhang” ahead of pivotal data for lonvo-z in hereditary angioedema mid-year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics upgraded at William Blair after clinical hold lifted
- Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair
- Intellia Resumes Key Trial and Expands ATM Program
- Intellia announces FDA lift of clinical hold on MAGNITUDE Phase 3 trial
- Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone